RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relmada Therapeutics, Inc. (RLMD) on June 1, 2022, covering events that occurred on May 25, 2022. The filing details the results of the Company's 2022 Annual Meeting of Stockholders held on that date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance metrics.
Material Changes and Corporate Actions
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the number of shares available for issuance by 3,900,000 to an aggregate of 5,400,000 shares.
- Authorized Share Increase: Stockholders approved an amendment to the Articles of Incorporation to increase authorized common stock from 50,000,000 to 150,000,000 shares.
- Director Election: Eric Schmidt was elected as a Class I Director for a 36-month term. Continuing directors include Charles J. Casamento, Sergio Traversa, John Glasspool, and Paul Kelly.
- Auditor Ratification: Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Voting Results and Participation
Of 29,369,490 eligible shares, 23,557,550 shares (approximately 80.2%) were present and voted. All four proposals submitted were approved.
| Proposal | For Votes | Against Votes | Abstentions |
|---|---|---|---|
| Election of Directors (Eric Schmidt) | 14,097,167 | 0 | 6,677,524 |
| Ratification of Auditors | 22,933,154 | 356,639 | 267,757 |
| Amendment to 2021 Equity Plan | 11,931,149 | 6,824,923 | 2,018,619 |
| Amendment to Articles of Incorporation | 14,921,614 | 8,245,591 | 390,345 |
Outlook, Risks, and Management Commentary
The filing does not contain specific management commentary on future financial outlook, risks, or contingencies beyond the standard disclosure of the approved corporate actions. The amendment to the equity plan suggests a strategic intent to retain talent through stock-based compensation.
Key Facts for Investor Verification
- Verify the dilution impact of the increased authorized share count (150,000,000 shares) and the expanded equity incentive pool (5,400,000 shares).
- Review the 2022 Proxy Statement (filed April 11, 2022) for detailed terms of the amended 2021 Equity Incentive Plan.
- Confirm the tenure and background of the newly elected director, Eric Schmidt.
- Monitor future filings for the actual issuance of shares under the amended equity plan.